The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
暂无分享,去创建一个
M. Braddock | I. McInnes | R. McQueenie | J. Brewer | R. Benson | P. Garside | J. Butcher | A. Platt
暂无分享,去创建一个
M. Braddock | I. McInnes | R. McQueenie | J. Brewer | R. Benson | P. Garside | J. Butcher | A. Platt